JP2013519653A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519653A5
JP2013519653A5 JP2012552401A JP2012552401A JP2013519653A5 JP 2013519653 A5 JP2013519653 A5 JP 2013519653A5 JP 2012552401 A JP2012552401 A JP 2012552401A JP 2012552401 A JP2012552401 A JP 2012552401A JP 2013519653 A5 JP2013519653 A5 JP 2013519653A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
scb
derivatives
gtx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552401A
Other languages
English (en)
Japanese (ja)
Other versions
JP6112867B2 (ja
JP2013519653A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051992 external-priority patent/WO2011098539A1/en
Publication of JP2013519653A publication Critical patent/JP2013519653A/ja
Publication of JP2013519653A5 publication Critical patent/JP2013519653A5/ja
Application granted granted Critical
Publication of JP6112867B2 publication Critical patent/JP6112867B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552401A 2010-02-10 2011-02-10 サキシトキシン誘導体での触覚の喪失の処置 Expired - Fee Related JP6112867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153234 2010-02-10
EP10153234.9 2010-02-10
US31290310P 2010-03-11 2010-03-11
US61/312,903 2010-03-11
PCT/EP2011/051992 WO2011098539A1 (en) 2010-02-10 2011-02-10 Treatment of loss of sense of touch with saxitoxin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016217143A Division JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Publications (3)

Publication Number Publication Date
JP2013519653A JP2013519653A (ja) 2013-05-30
JP2013519653A5 true JP2013519653A5 (enExample) 2014-03-13
JP6112867B2 JP6112867B2 (ja) 2017-04-12

Family

ID=43828310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012552401A Expired - Fee Related JP6112867B2 (ja) 2010-02-10 2011-02-10 サキシトキシン誘導体での触覚の喪失の処置
JP2016217143A Pending JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016217143A Pending JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Country Status (6)

Country Link
US (2) US9107925B2 (enExample)
EP (1) EP2533785B1 (enExample)
JP (2) JP6112867B2 (enExample)
CN (1) CN102811722A (enExample)
ES (1) ES2484315T3 (enExample)
WO (1) WO2011098539A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
EP2638908A1 (en) * 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
KR102787826B1 (ko) 2013-03-15 2025-03-31 더 칠드런스 메디칼 센터 코포레이션 지속성 국소 마취용 네오삭시톡신 조합 제형
CA2944549A1 (en) * 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process
JP2020515611A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
CA3058214A1 (en) 2017-03-29 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University 11,13-modified saxitoxins for the treatment of pain
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP4196482B1 (en) * 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
WO2022112887A1 (en) * 2020-11-25 2022-06-02 Algenis Method of treating acute nociceptive pain in mammals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
MXPA04004543A (es) * 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
EP1796676B1 (en) * 2004-05-07 2016-03-09 Phytotox Limited Transdermal administration of phycotoxins
BRPI0510759A (pt) * 2004-05-07 2007-11-20 Phytotox Ltd método de facilitar a cura de um ferimento
AU2005287511A1 (en) 2004-09-21 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
KR20070092698A (ko) 2004-09-22 2007-09-13 라보라토리오스 델 드라. 에스테브.에스.에이. 말초 신경적으로 유발된 신경병증성 통증을 치료하기 위한테트로도톡신 및 그것의 유도체
WO2007110221A1 (en) 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置

Similar Documents

Publication Publication Date Title
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MY202837A (en) Lipids for lipid nanoparticle delivery of active agents
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
JP2013542247A5 (enExample)
RU2013142448A (ru) Новые сульфонаминохинолиновые антагонисты гепсидина
KR20150013527A (ko) 항염증 활성과 접합된 증진된 항인플루엔자제
JP2013508279A5 (enExample)
JP2009504763A5 (enExample)
JP2015530382A5 (enExample)
EP2581376A4 (en) MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF
JP2014508804A5 (enExample)
RU2011146005A (ru) Композиции для лечения воспаления и способы лечения воспаления
JP2013522229A5 (enExample)
JP2014503560A5 (enExample)
ES2698363T3 (es) Composiciones de oxprenolol para tratar el cáncer
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
JP2017525718A5 (enExample)
JP2013518036A5 (enExample)
JP2017513824A5 (enExample)
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AR075626A1 (es) Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso.
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
NO20082181L (no) Formuleringer av Fispemifen